Funding for this research was provided by:
Japanese Association for Acute Medicine (2014-01)
Received: 24 February 2021
Accepted: 16 April 2021
First Online: 29 April 2021
: All collaborating hospitals obtained approval of their individual Institutional Review Board (IRB) for conducting research with human participants (approval number JAAM, 2014-01 from Japanese Association for Acute Medicine; approval number 014-0307 from Hokkaido University Graduate School of Medicine, head institute of the FORECAST group; and approval number 20150056 from the Keio University School of Medicine Keio, institute of the corresponding author).
: Not applicable.
: Dr. Fujishima reports grants and personal fees from Asahi Kasei Japan Co.; grants from Shionogi Co, Ltd.; grants from Chugai Pharmaceuticals Co., Ltd.; grants from Otsuka Pharmaceutical Co., Ltd.; grants from Teijin Pharma, Ltd.; grants from Pfizer Inc.; grants from Tsumura & Co.; grants from Astellas Pharma Inc.; and personal fees from Takeda Pharmaceutical Co., Ltd., outside the submitted work. Dr. Gando reports personal fees from ASAHIKASEI PHARMA AMERICA, personal fees from ASAHIKASEI PHARMA JAPAN, and personal fees from GRIFOLS, outside the submitted work.